Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in antiviral therapy

D Pavan-Langston, R H Langston

    International Ophthalmology Clinics
    |January 1, 1975
    PubMed
    Summary

    Vidarabine (Ara A) and trifluridine (F3T) are effective treatments for ocular herpes, outperforming idoxuridine (IDU). An IDU ocular insert offers improved drug delivery and patient convenience compared to traditional drop-ointment therapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    What is the risk of complications from cataract surgery in patients taking anticoagulants?

    Cleveland Clinic journal of medicine·2001
    Same author

    Herpes simplex of the ocular anterior segment.

    Current clinical topics in infectious diseases·2000
    Same author

    Management of the retinal impact site after intraocular foreign body trauma.

    Ophthalmology·2000
    Same author

    Retraction: A rabbit model for human cytomeglovirus--induced chorioretinal disease (J Infect Dis 1993;168:336-44).

    The Journal of infectious diseases·1998
    Same author

    AIDS and the anterior segment.

    International ophthalmology clinics·1998
    Same author

    Long-term oral acyclovir therapy. Effect on recurrent infectious herpes simplex keratitis in patients with and without grafts.

    Ophthalmology·1996

    Area of Science:

    • Ophthalmology
    • Virology
    • Pharmacology

    Background:

    • Ocular herpes infections pose a significant therapeutic challenge.
    • Traditional treatments like idoxuridine (IDU) have limitations in efficacy and administration.
    • Alternative therapies such as photodynamic inactivation and cryotherapy show promise but are hindered by side effects.

    Purpose of the Study:

    • To compare the efficacy of antimetabolites vidarabine (Ara A) and trifluridine (F3T) against idoxuridine (IDU) for ocular herpes.
    • To evaluate the preclinical performance of an idoxuridine (IDU) ocular insert compared to conventional drop-ointment therapy.
    • To assess the therapeutic potential and limitations of photodynamic inactivation and cryotherapy in managing ocular herpes.

    Main Methods:

    • Clinical trials comparing Ara A, F3T, and IDU for ocular herpes treatment.
    • Preclinical trials evaluating an IDU ocular insert versus IDU drop-ointment.
    • Review of clinical trial data for photodynamic inactivation and cryotherapy efficacy and side effects.

    Main Results:

    • Ara A and F3T demonstrated significantly superior efficacy over IDU in treating various forms of ocular herpes.
    • No significant difference in efficacy was found between Ara A and F3T.
    • The IDU ocular insert showed improved efficacy, reduced drug exposure by 40%, and enhanced patient compliance compared to IDU drop-ointment.
    • Photodynamic inactivation and cryotherapy exhibited therapeutic efficacy but were associated with undesirable side effects.

    Conclusions:

    • Vidarabine (Ara A) and trifluridine (F3T) represent advancements in ocular herpes treatment over idoxuridine (IDU).
    • The IDU ocular insert offers a more convenient and effective drug delivery system for ocular herpes management.
    • Further development of photodynamic inactivation and cryotherapy may be limited by safety concerns.

    Related Experiment Videos